• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Wednesday, March 29, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Researchers identify biomarkers of response to treatment in invasive breast cancer

Bioengineer by Bioengineer
December 8, 2016
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

CHAPEL HILL – Why do some breast cancers respond to treatment while others resist it? A study led by researchers at the University of North Carolina Lineberger Comprehensive Cancer Center may provide insight into this important question.

The researchers report at the San Antonio Breast Cancer Symposium that they have identified biomarkers they believe can be used as part of a larger model to predict how patients with HER2-positive operative breast cancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemotherapy.

"We're trying to find biomarkers for resistance to trastuzumab treatment and chemotherapy," said the study's first author Maki Tanioka, MD, PhD, a postdoctoral research associate at UNC Lineberger. "What's the cause of response? What's the cause of resistance? That's what we are trying to identify in this genomic study."

Tanioka and his colleagues analyzed multiple biologic features of cancer cells from 213 patients treated for HER2-positive breast cancer through a National Cancer Institute cooperative group clinical trial, CALGB 40601. The biologic features included multiple kinds of genetic information such as DNA mutations, DNA copy number and RNA gene expression data. The researchers found that certain gene signatures, and either having too many, or too few, of certain genes were predictive of whether patients responded to treatment, and that combining those two features was the most effective method of predicting response.

Examining features like mutations, amplifications or deletions of genes in tumor cells, the overall subtype of the tumor, as well as indicators of immune responses helped the researchers predict response. The researchers also determined that amplification of a specific chromosome, and a particular gene called MAPK14 on that chromosome, may be a predictor of sensitivity to treatment, while deletions of other genes predicted resistance.

The researchers say the next step is to identify another set of data to validate and broaden their findings.

"HER2-positive breast cancer is genomically heterogeneous," Tanioka said. "Therefore, we need a model that incorporates all these different features. We are actively seeking a set of patient data that we can use to validate the biomarkers we have identified so we can create a comprehensive predictive model of response to allow us to better tailor treatment."

###

In addition to Tanioka, other authors include: C. Fan, L.A. Carey, T. Hyslop, B.N. Pitcher, J. Parker, K.A. Hoadley, N.L. Henry, S. Tolaney, C. Dang, I.E. Krop, L. Harris, D.A. Berry, E. Mardis, C.M. Perou, E.P. Winer, and C.A. Hudis.

Media Contact

Laura Oleniacz
[email protected]
919-445-4219

http://cancer.med.unc.edu/

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

Alexandre Colas, Ph.D.

Heart attack study could change the game in regenerative medicine

March 29, 2023
Figure 1

Senescence and extracellular vesicles: novel partners in vascular amyloidosis

March 29, 2023

Groundbreaking lymphoma tumor model paves way for new therapies

March 29, 2023

Mimicking biological enzymes may be key to hydrogen fuel production

March 29, 2023
Please login to join discussion

POPULAR NEWS

  • ChatPandaGPT

    Insilico Medicine brings AI-powered “ChatPandaGPT” to its target discovery platform

    67 shares
    Share 27 Tweet 17
  • Northern and southern resident orcas hunt differently, which may help explain the decline of southern orcas

    44 shares
    Share 18 Tweet 11
  • Skipping breakfast may compromise the immune system

    43 shares
    Share 17 Tweet 11
  • Insular dwarfs and giants more likely to go extinct

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Heart attack study could change the game in regenerative medicine

Senescence and extracellular vesicles: novel partners in vascular amyloidosis

Groundbreaking lymphoma tumor model paves way for new therapies

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 48 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In